# Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer

Source: https://onco.cc/trials/nct06700603/  
OnCo record `nct06700603` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of fluorouracil (5-FU) in pancreatic cancer, run by Rui-hua Xu, MD, PhD, not yet recruiting.

## Summary

Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer is a phase 2, interventional study registered as NCT06700603 by Rui-hua Xu, MD, PhD, with a registry enrolment figure of 48 participants, started 2024-11-20 and due to reach its primary completion in 2025-12-31. Interventions recorded: Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate. Conditions listed: Pancreatic Cancer. Primary outcome: (PFS). Pancreatic eligibility wording from the registry: "histologically or cytologically confirmed as pancreatic ductal adenocarcinoma;". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06700603
- Phase: 2
- Setting: Phase II Clinical Study of Irinotecan Liposome Combined with 5-FU/LV for the Patients with Advanced Pancreatic Cancer Who Failed to Receive Irinotecan-containing Regimens
- Sponsor: Rui-hua Xu, MD, PhD
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT06700603: https://clinicaltrials.gov/study/NCT06700603

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06700603.json